FDA alerts medical personnel about vape risk

  • By

Washington, DC --  The FDA has issued an alert to medical personnel and consumers about recent reported cases of respiratory illnesses connected to eCigarette use.

As of Aug. 27, 2019, 215 possible cases have been reported from 25 states, and additional reports of pulmonary illness are under investigation. While some cases in each of the states are similar and appear to be linked to e-cigarette product use, more information is needed to determine what is causing the respiratory illnesses.

Patients have generally reported patients reported that symptoms started gradually and included  breathing difficulty, shortness of breath, and/or chest pain.

Many also reported vomiting, diarrhea, and other symptoms such as fevers or fatigue.

Patients have also acknowledged recent use of tetrahydrocannabinol (THC)-containing e-cigarette products while speaking to healthcare personnel, or in follow-up interviews by health department staff.

The FDA is currently analyzing around 80 samples submitted from the states for their contents, whether they contain nicotine, substances, such as THC or other cannabinoids, or other chemicals and ingredients.

While the investigation is ongoing, the FDA suggests If you are concerned about these specific health risks, consider refraining from the use of e-cigarette products.

Anyone who does use e-cigarette products should not buy these products off the street (e.g., e-cigarette products with THC or other cannabinoids).
Anyone should not modify e-cigarette products or add any substances to these products that are not intended by the manufacturer.

Around the Web


0 Comments Write your comment

    1. Loading...